Cue Biopharma, Inc. (CUE) intrinsic value & 10-year financials
Cue Biopharma, Inc. (CUE) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 57.5% a year to $27.5M, with an average return on invested capital of 230.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $16.71
- Market cap
- $1.6B
- Revenue (FY2025)
- $27.5M
- Revenue growth (10-yr CAGR)
- 57.5%
- ROIC (10-yr avg)
- 230.8%
- Free cash flow (FY2025)
- -$21.9M
CUE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $27.5M | -$26.6M | -$0.28 | -$21.9M | -96.7% | 2271.3% |
| FY2024 | $9.3M | -$40.7M | -$0.72 | -$36.4M | -446.9% | 2082.8% |
| FY2023 | $5.5M | -$50.7M | -$1.11 | -$40.0M | -949.9% | -337.6% |
| FY2022 | $1.2M | -$53.0M | -$1.49 | -$42.0M | -4274.3% | -292.7% |
| FY2021 | $14.9M | -$44.2M | -$1.41 | -$39.8M | -292.6% | -690.7% |
| FY2020 | $3.2M | -$44.8M | — | -$33.1M | -1428.0% | -498.9% |
| FY2019 | $3.5M | -$36.7M | — | -$30.8M | -1063.2% | -315.8% |
| FY2018 | $1.1M | -$39.0M | — | -$28.3M | -3386.7% | -81.0% |
| FY2017 | — | -$23.2M | — | -$13.2M | — | -60.5% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cue Biopharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cue Biopharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -13.3% ROIC.
Cue Biopharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cue Biopharma, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-9.30 per share.